Loveday C - Search Results

1

Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.

Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD; EuroSIDA Study Group. Cozzi-Lepri A, et al. Among authors: loveday c. Antivir Ther. 2005;10(7):791-802. Antivir Ther. 2005. PMID: 16312176

2

Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.

Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L; EuroSIDA Study Group. Cabrera C, et al. Among authors: loveday c. Antivir Ther. 2004 Oct;9(5):787-800. Antivir Ther. 2004. PMID: 15535417

3

HIV-1 subtypes and response to combination antiretroviral therapy in Europe.

Bannister WP, Ruiz L, Loveday C, Vella S, Zilmer K, Kjaer J, Knysz B, Phillips AN, Mocroft A; EuroSIDA Study Group. Bannister WP, et al. Among authors: loveday c. Antivir Ther. 2006;11(6):707-15. Antivir Ther. 2006. PMID: 17310815

4

Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.

Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD; EuroSIDA Study Group. Cozzi-Lepri A, et al. Among authors: loveday c. AIDS. 2007 Mar 30;21(6):721-32. doi: 10.1097/QAD.0b013e3280141fdf. AIDS. 2007. PMID: 17413693

5

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte Ad, Clotet B, Lundgren JD; EuroSIDA study group. Bannister WP, et al. Among authors: loveday c. AIDS. 2008 Jan 30;22(3):367-76. doi: 10.1097/QAD.0b013e3282f3cc35. AIDS. 2008. PMID: 18195563

6

Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.

Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, Sabin CA, Doerr HW, Johnson MA, Loveday C, Miller V; Royal Free Centre for HIV Medicine; Goethe Universität Clinic Cohort. Phillips AN, et al. Among authors: loveday c. J Infect Dis. 2002 Oct 15;186(8):1086-91. doi: 10.1086/343801. Epub 2002 Sep 30. J Infect Dis. 2002. PMID: 12355358 Free article.

7

Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection.

Phillips AN, Youle MS, Lampe F, Johnson M, Sabin CA, Lepri AC, Loveday C. Phillips AN, et al. Among authors: loveday c. AIDS. 2003 May 2;17(7):1009-16. doi: 10.1097/00002030-200305020-00009. AIDS. 2003. PMID: 12700450

8

Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?

Moore AL, Youle M, Lipman M, Cozzi-Lepri A, Lampe F, Madge S, Nesaratnam S, Tyrer M, Cuthbertson Z, Ransom D, Loveday C, Johnson MA, Phillips AN; Royal Free Centre for HIV Medicine. Moore AL, et al. Among authors: loveday c. AIDS. 2002 Mar 8;16(4):615-8. doi: 10.1097/00002030-200203080-00013. AIDS. 2002. PMID: 11873005

9

Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years.

Lampe FC, Johnson MA, Lipman M, Loveday C, Youle M, Ransom D, Sabin CA, Tyrer M, Phillips AN. Lampe FC, et al. Among authors: loveday c. AIDS. 2003 Mar 28;17(5):768-70. doi: 10.1097/01.aids.0000050876.71999.11. AIDS. 2003. PMID: 12646806 No abstract available.

10

Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen.

Youle M, Tyrer M, Fisher M, Lampe F, Wilson D, Ransom D, Story A, Mocroft A, Loveday C, Johnson MA, Phillips AN. Youle M, et al. Among authors: loveday c. J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):58-61. doi: 10.1097/00126334-200201010-00008. J Acquir Immune Defic Syndr. 2002. PMID: 11782591 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters